|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Clinical Therapy Trials—Drugs |
Department of Neurosurgery, University Hospital Eppendorf, Hamburg, Germany (M.W.); Guilford Pharmaceuticals, Baltimore, MD 21224, USA (D.C.H., E.B.); Aventis Pharma France, Paris, France (P.D., R.O.); Walton Centre for Neurology and Neurosurgery, Liverpool, UK (P.C.W.); Department of Neurosurgery, Western General Hospital, Edinburgh, Scotland (I.R.W.); Department of Neurosurgery, Topeliuksenkatu 5, Helsinki, Finland (J.J.); Department of Neurosurgery, Chaim Sheba Medical Center, Tel-Aviv, Israel (Z.R.)
3 Address correspondence and reprint requests to Manfred Westphal, Department of Neurosurgery, University Hospital Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany (Westphal{at}uke.uni-hamburg.de).
Abstract
A previous placebo-controlled trial has shown that biodegradable 1,3-bis
(2-chloroethyl)-1-nitrosourea (BCNU) wafers (Gliadel wafers) prolong survival
in patients with recurrent glioblastoma multiforme. A previously completed
phase 3 trial, also placebo controlled, in 32 patients with newly diagnosed
malignant glioma also demonstrated a survival benefit in those patients
treated with BCNU wafers. Because of the small number of patients in that
trial, a larger phase 3 trial was performed to confirm these results. Two
hundred forty patients were randomized to receive either BCNU or placebo
wafers at the time of primary surgical resection; both groups were treated
with external beam radiation postoperatively. The two groups were similar for
age, sex, Karnofsky performance status (KPS), and tumor histology. Median
survival in the intent-to-treat group was 13.9 months for the BCNU
wafer-treated group and 11.6 months for the placebo-treated group (log-rank
P-value stratified by country = 0.03), with a 29% reduction in the
risk of death in the treatment group. When adjusted for factors affecting
survival, the treatment effect remained positive with a risk reduction of 28%
(P = 0.03). Time to decline in KPS and in 10/11 neuroperformance
measures was statistically significantly prolonged in the BCNU wafer-treated
group (P 
0.05). Adverse events were comparable for the 2 groups,
except for CSF leak (5% in the BCNU wafer-treated group vs. 0.8% in the
placebo-treated group) and intracranial hypertension (9.1% in the BCNU
wafer-treated group vs. 1.7% in the placebo group). This study confirms that
local chemotherapy with BCNU wafers is well tolerated and offers a survival
benefit to patients with newly diagnosed malignant glioma.
This article has been cited by other articles:
|
|
 |
|
  F. J. Attenello, D. Mukherjee, G. Datoo, M. J. McGirt, E. Bohan, J. D. Weingart, A. Olivi, A. Quinones-Hinojosa, and H. Brem Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience Ann. Surg. Oncol., October 1, 2008; 15(10): 2887 - 2893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Linnebank, A. Semmler, S. Moskau, Y. Smulders, H. Blom, and M. Simon The methylenetetrahydrofolate reductase (MTHFR) variant c.677C>T (A222V) influences overall survival of patients with glioblastoma multiforme Neuro-oncol, August 1, 2008; 10(4): 548 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Y. Wen and S. Kesari Malignant Gliomas in Adults N. Engl. J. Med., July 31, 2008; 359(5): 492 - 507. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Reardon, M. R. Zalutsky, G. Akabani, R. E. Coleman, A. H. Friedman, J. E. Herndon II, R. E. McLendon, C. N. Pegram, J. A. Quinn, J. N. Rich, et al. A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost Neuro-oncol, April 1, 2008; 10(2): 182 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Ewend, S. Brem, M. Gilbert, R. Goodkin, P. L. Penar, M. Varia, S. Cush, and L. A. Carey Treatment of Single Brain Metastasis with Resection, Intracavity Carmustine Polymer Wafers, and Radiation Therapy Is Safe and Provides Excellent Local Control Clin. Cancer Res., June 15, 2007; 13(12): 3637 - 3641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kunwar, M. D. Prados, S. M. Chang, M. S. Berger, F. F. Lang, J. M. Piepmeier, J. H. Sampson, Z. Ram, P. H. Gutin, R. D. Gibbons, et al. Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group J. Clin. Oncol., March 1, 2007; 25(7): 837 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Otterson, M. A. Villalona-Calero, S. Sharma, M. G. Kris, A. Imondi, M. Gerber, D. A. White, M. J. Ratain, J. H. Schiller, A. Sandler, et al. Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs Clin. Cancer Res., February 15, 2007; 13(4): 1246 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Weingart, S. A. Grossman, K. A. Carson, J. D. Fisher, S. M. Delaney, M. L. Rosenblum, A. Olivi, K. Judy, S. B. Tatter, and M. E. Dolan Phase I Trial of Polifeprosan 20 With Carmustine Implant Plus Continuous Infusion of Intravenous O6-Benzylguanine in Adults With Recurrent Malignant Glioma: New Approaches to Brain Tumor Therapy CNS Consortium Trial J. Clin. Oncol., February 1, 2007; 25(4): 399 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Bodell, A. P. Bodell, and D. D. Giannini Levels and distribution of BCNU in GBM tumors following intratumoral injection of DTI-015 (BCNU-ethanol) Neuro-oncol, January 1, 2007; 9(1): 12 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. ter Horst, S. M. Verwijnen, E. Brouwer, R. C. Hoeben, M. de Jong, B. H.C.G.M. de Leeuw, and P. A.E. Sillevis Smitt Locoregional Delivery of Adenoviral Vectors J. Nucl. Med., September 1, 2006; 47(9): 1483 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Olesen, M. G Baker, T. Freund, M. di Luca, J. Mendlewicz, I. Ragan, and M. Westphal Consensus document on European brain research J. Neurol. Neurosurg. Psychiatry, August 1, 2006; 77(suppl_1): i1 - i49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner Recent Advances in the Treatment of Malignant Astrocytoma J. Clin. Oncol., March 10, 2006; 24(8): 1253 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Gilbert New treatments for malignant gliomas: careful evaluation and cautious optimism required. Ann Intern Med, March 7, 2006; 144(5): 371 - 373. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Stupp, M. E. Hegi, M. J. van den Bent, W. P. Mason, M. Weller, R. O. Mirimanoff, J. G. Cairncross, and on behalf of the European Organisation for Researc Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist, February 1, 2006; 11(2): 165 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Combs, C. Thilmann, L. Edler, J. Debus, and D. Schulz-Ertner Efficacy of Fractionated Stereotactic Reirradiation in Recurrent Gliomas: Long-Term Results in 172 Patients Treated in a Single Institution J. Clin. Oncol., December 1, 2005; 23(34): 8863 - 8869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Brem, S. A. Grossman, K. A. Carson, P. New, S. Phuphanich, J. B. Alavi, T. Mikkelsen, J. D. Fisher, and for the New Approaches to Brain Tumor Therapy CNS Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma Neuro-oncol, July 1, 2005; 7(3): 246 - 253. [Abstract] [PDF]
|
|
|
|
 |
|
 S. M. Chang, I. F. Parney, W. Huang, F. A. Anderson Jr, A. L. Asher, M. Bernstein, K. O. Lillehei, H. Brem, M. S. Berger, E. R. Laws, et al. Patterns of Care for Adults With Newly Diagnosed Malignant Glioma JAMA, February 2, 2005; 293(5): 557 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Benny, M. Duvshani-Eshet, T. Cargioli, L. Bello, A. Bikfalvi, R. S. Carroll, and M. Machluf Continuous Delivery of Endogenous Inhibitors from Poly(Lactic-Co-Glycolic Acid) Polymeric Microspheres Inhibits Glioma Tumor Growth Clin. Cancer Res., January 15, 2005; 11(2): 768 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Weber and E. A. Goebel Cerebral edema associated with Gliadel wafers: Two case studies Neuro-oncol, January 1, 2005; 7(1): 84 - 89. [Abstract] [PDF]
|
|
|
|
 |
|
 B. J. May, M. Guarnieri, B. S. Carson Sr, A. Bachani, and G. I. Jallo Long-term Effects of Carboplatin Brainstem Infusions on Hearing Thresholds in Monkeys Arch Otolaryngol Head Neck Surg, December 1, 2004; 130(12): 1411 - 1415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Hall, B. A. Moffat, J. Stojanovska, T. D. Johnson, Z. Li, D. A. Hamstra, A. Rehemtulla, T. L. Chenevert, J. Carter, D. Pietronigro, et al. Therapeutic Efficacy of DTI-015 using Diffusion Magnetic Resonance Imaging as an Early Surrogate Marker Clin. Cancer Res., December 1, 2004; 10(23): 7852 - 7859. [Abstract] [Full Text] [PDF]
|
|
|
|
